Loading stock data…
IMDX
$4.18+0.17 (+4.24%)
Market ClosedLast close May 1
Insight Molecular Diagnostics Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insight Molecular Diagnostics Inc. in the Healthcare sector is trading at $4.18. The stock is currently 51% below its 52-week high of $8.51, remaining 11.3% below its 200-day moving average. Technical signals show neutral RSI of 66 and bullish MACD crossover, explaining why IMDX maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 66) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.18
Potential Upside
5%
Whystock Fair Value$4.39
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Buy
Mean target$8.33+99.4%
Range$4.00 – $12.00
Fundamentals
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$120.63M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
202.80%
Volume
Today's trading volume
135,739
Recent News
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx Milestones
Insight Molecular Diagnostics is back in focus as analysts update their narrative around a new $12 price target while the fair value estimate holds at $8.33. That shift in target is being linked to views on funding visibility after the recent $26m offering and expectations around an upcoming FDA submission for GraftAssureDx, as well as differing opinions on execution and financing risk. Read on to see how these moving pieces shape the evolving story and what to watch as new information...
Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst
The latest update to Insight Molecular Diagnostics has seen the analyst price target move to US$12, while the fair value estimate remains at US$8.33 per share. Analysts linking this shift to the recent US$26M capital raise and the upcoming GraftAssureDx FDA submission see both reduced near term financing risk and a potential regulatory catalyst as key drivers. Read on to see how these moving parts shape the evolving story and what to watch as the narrative develops. Stay updated as the Fair...
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst
The raised price target from $8 to $12 puts Insight Molecular Diagnostics more firmly on the radar for investors tracking valuation shifts. Analysts are linking this higher price target to the recent $26,000,000 capital raise and the upcoming FDA submission for GraftAssureDx, which they identify as key factors behind the updated outlook. The following sections explain how this evolving analyst narrative could influence how you follow the story from here. Stay updated as the Fair Value for...
Insight Molecular Diagnostics Inc. Q4 2025 Earnings Call Summary
Moby summary of Insight Molecular Diagnostics Inc.'s Q4 2025 earnings call
Insight Molecular Diagnostics: Q4 Earnings Snapshot
NASHVILLE, Tenn. AP) — Insight Molecular Diagnostics Inc. IMDX) on Thursday reported a loss of $23 million in its fourth quarter.